Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACoN: Biomarker Exploration in Aging, Cognition and Neurodegeneration
NCT03860857Phase 3Recruiting
- Sponsor
- University of California, Irvine
- Start
- May 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of florquinitau in Alzheimer's disease (AD) (9 arms), sponsored by University of California, Irvine. Primary endpoint: Clinical Dementia Rating - Sum of Box at 5 years. Started May 2018; status: recruiting.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03860857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860857.